UCB: Deutsche Bank upgrades stock

(CercleFinance.com) - Deutsche Bank announced on Wednesday that it had upgraded its recommendation on the share of Belgian group UCB from "hold" to "buy", with a target price raised from 85 to 100 euros.


In a research note, the analyst explains that its upgrade comes after the "solid" results published for the first half of the year, and ahead of the US FDA's eagerly-awaited decision on the approval of Bimzelx for the treatment of psoriasis, expected by the end of September.

While he notes that this date is not without risk, given the postponements of product launches that have marked the laboratory's history, the intermediary believes that the rest of the dossier is relatively low-risk.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.